Dupont Capital Management Corp Has $214,000 Stake in Emergent BioSolutions Inc. (NYSE:EBS)

Dupont Capital Management Corp trimmed its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) by 28.1% in the third quarter, HoldingsChannel reports. The firm owned 10,208 shares of the biopharmaceutical company’s stock after selling 3,999 shares during the period. Dupont Capital Management Corp’s holdings in Emergent BioSolutions were worth $214,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of EBS. State Street Corp increased its stake in shares of Emergent BioSolutions by 19.6% in the 2nd quarter. State Street Corp now owns 4,150,632 shares of the biopharmaceutical company’s stock valued at $128,836,000 after buying an additional 681,162 shares during the period. BlackRock Inc. increased its stake in shares of Emergent BioSolutions by 8.1% in the 1st quarter. BlackRock Inc. now owns 8,731,904 shares of the biopharmaceutical company’s stock valued at $358,533,000 after buying an additional 655,003 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Emergent BioSolutions in the 1st quarter valued at $14,699,000. Dimensional Fund Advisors LP increased its stake in shares of Emergent BioSolutions by 33.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,368,661 shares of the biopharmaceutical company’s stock valued at $56,199,000 after buying an additional 342,964 shares during the period. Finally, Federated Hermes Inc. increased its stake in shares of Emergent BioSolutions by 45,289.3% in the 1st quarter. Federated Hermes Inc. now owns 298,208 shares of the biopharmaceutical company’s stock valued at $12,244,000 after buying an additional 297,551 shares during the period. 80.44% of the stock is owned by institutional investors and hedge funds.

Emergent BioSolutions Stock Performance

EBS stock opened at $13.43 on Tuesday. The business’s 50-day moving average price is $12.42 and its two-hundred day moving average price is $20.96. The company has a current ratio of 4.17, a quick ratio of 2.13 and a debt-to-equity ratio of 0.71. The firm has a market cap of $670.00 million, a PE ratio of 17.22 and a beta of 0.89. Emergent BioSolutions Inc. has a 1-year low of $10.61 and a 1-year high of $52.28.

Emergent BioSolutions (NYSE:EBS – Get Rating) last posted its earnings results on Tuesday, November 8th. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($1.21). The business had revenue of $240.00 million for the quarter, compared to the consensus estimate of $268.17 million. Emergent BioSolutions had a return on equity of 9.52% and a net margin of 3.54%. As a group, research analysts forecast that Emergent BioSolutions Inc. will post -2.65 earnings per share for the current year.

Analysts Set New Price Targets

EBS has been the subject of several research reports. StockNews.com cut Emergent BioSolutions from a “hold” rating to a “sell” rating in a research note on Monday, November 14th. Benchmark lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Thursday, November 10th. Cowen reduced their price target on Emergent BioSolutions to $25.00 in a research report on Tuesday, November 15th. Finally, Chardan Capital reduced their price target on Emergent BioSolutions from $65.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, November 9th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Emergent BioSolutions has an average rating of “Hold” and an average target price of $46.50.

Emergent BioSolutions Profile

(Get Rating)

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.